AstraZeneca fight rumbles on

The proposed takeover of AstraZeneca is proving to be one of the most controversial yet.

The £63bn takeover offer for Anglo-Swedish pharmaceutical group AstraZeneca by its US rival Pfizer is shaping up to be one of the most controversial takeover battles to involve a UK-based company.

British politicians fear that the enlarged Pfizer would cut research spending in the UK, endangering jobs and damaging Britain's science base. On the other side of the Atlantic, there has been considerable criticism of Pfizer's proposal to domicile the combined group in the UK for tax purposes.

Subscribe to MoneyWeek

Become a smarter, better informed investor with MoneyWeek.

In the past week, Pfizer's chief executive appeared before MPs in an attempt to reassure them about his firm's plans for investment and employment. Meanwhile, the firm is reported to be planning an increased hostile bid if it's unable to win the support of AstraZeneca's board.

What the commentators said

Normally in these situations, the takeover will go ahead as seen in Kraft's acquisition of Cadbury in 2010. Dangle the prospect of "jam today" in front of shareholders and they will bite, regardless of whether it represents a good long-term outcome.

Advertisement
Advertisement - Article continues below

This reflects the "dysfunctional nature of the relationship" between company management, fund managers, the investors in the funds they run and the rest of society, agreed John Plender in the FT.

Executives are incentivised to boost short-term earnings through takeovers and cost-cutting, while fund managers are judged on short-term performance and leap at the chance to make a profit.

Yet there is ample evidence that takeovers are "a highly effective mechanism for uncreative destruction" rather than a boon to either investors or the economy: take Pfizer itself, which has spent $240bn on three big takeovers in 15 years, yet has a market cap today of just $185bn. "The only consistent winners are the investment bankers and other advisers."

That may be true in general, but this particular deal "is a poor test case for almost any question about big corporate acquisitions", said Edward Hadas on Breakingviews.com.

"The would-be US acquirer, the British target, the UK government and the whole pharmaceutical industry are all tainted. They are guilty, respectively, of a tax fixation, cutting research, empty words and inadequate drug discovery. So there is really no one with the moral authority to say whether this is a good deal."

The best outcome would be for the UK and US to tackle the weakest part of the bid: Pfizer's attempt to game the tax system. If the firm is still interested after that, it can come back with a fresh bid.

Advertisement

Recommended

Visit/investments/stockmarkets/600634/why-investors-should-be-cautiously-bullish-for-2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020
Visit/investments/stocks-and-shares/share-tips/600636/class-acts-going-cheap-buy-into-europes-best
Share tips

Class acts going cheap: buy into Europe’s best bargains

Value investing appears to be making a comeback, while shares on this side of the Atlantic are more appealing on metrics such as price/earnings ratios…
16 Jan 2020
Visit/investments/investment-strategy/600637/buying-shares-can-be-a-tricky-business
Investment strategy

Buying shares can be a tricky business

A tip gone bad reminds John Stepek that buying shares in troubled companies in the hope that they can turn themselves around doesn't always pay off.
16 Jan 2020
Visit/519806/cineworld-heads-to-canada
Stocks and shares

Cineworld heads to Canada with purchase of Cineplex

Cineworld's purchase of its Canadian rival Cineplex will allow it to tap the $770m annual revenues from the Canadian box office.
19 Dec 2019

Most Popular

Visit/economy/uk-economy/600824/how-the-bbc-can-survive-the-end-of-the-tv-licence
UK Economy

How the BBC can survive the end of the TV licence

Th TV licence that funds the BBC is looking way past its sell-by date, says Matthew Lynn. Here's how it could survive without it
16 Feb 2020
Visit/economy/uk-economy/600837/rishi-sunak-new-chancellor-spending-splurge
UK Economy

Britain has a new chancellor – get ready for a major spending splurge

The departure of Sajid Javid as chancellor and the appointment of Rishi Sunak marks a change in the style of our politics. John Stepek explains what's…
14 Feb 2020
Visit/investments/property/600826/living-on-a-houseboat-the-pros-and-cons-of-a-floating-home
Property

Living on a houseboat: the pros and cons of a floating home

Living on a houseboat sounds romantic and peaceful. But it’s not as straightforward as it looks, says Nicole Garcia Merida
14 Feb 2020
Visit/investments/commodities/600729/the-rare-earth-metal-that-wont-be-a-secret-for-long
Sponsored

The rare earth metal that won't be a secret for long

SPONSORED CONTENT – You can’t keep a good thing hidden forever; now is the time to consider Pensana Rare Earths and the rare earth metals NdPr.
31 Jan 2020